India’s Newest Entrant to the Plant Protein Category Is Dubbed Its ‘Lightest’ Powder Yet

Why It Matters

Improved digestibility makes the product appealing to the majority of Indians who lack sufficient protein, positioning Immunosciences to capture a sizable slice of a fast‑growing $1.6 billion market and draw further investor interest.

Key Takeaways

• Immunosciences launches Pure Plant Protein with DigeZyme enzyme blend.
• Powder provides 24 g protein per 30 g scoop, includes BCAAs.
• Targets 73 % of Indians lacking adequate daily protein.
• India plant protein market valued at $1.6 B, expanding rapidly.
• GLP‑1 drug users risk muscle loss, increasing protein demand.

Pulse Analysis

India’s protein landscape is at a crossroads. While the country’s per‑capita protein intake lags behind global averages, a burgeoning $1.6 billion plant‑protein market is responding to shifting dietary preferences, rising health awareness, and the fallout from GLP‑1 weight‑loss drugs that can erode muscle mass. Consumers—particularly vegetarians and time‑pressed urban professionals—are seeking convenient, high‑quality protein sources that fit clean‑eating standards, creating fertile ground for innovative supplements.

Immunosciences’ Pure Plant Protein differentiates itself through a DigeZyme multi‑enzyme blend that enhances amino‑acid absorption and mitigates the bloating often associated with plant proteins. By combining pea, brown‑rice and pumpkin‑seed isolates, the formula delivers a complete amino‑acid profile, including over 4 g of branched‑chain amino acids per scoop. The inclusion of prebiotic inulin, probiotic Bacillus coagulans and monk‑fruit sweetener further positions the product as a gut‑friendly, low‑sugar alternative for everyday nutrition, directly addressing the digestibility concerns cited by Indian consumers.

The launch aligns with a wave of capital inflows into India’s alternative‑protein sector. Recent deals—Marico’s $25 million acquisition of a 60 % stake in Cosmix Wellness and Earthful’s $2.9 million raise—signal confidence that plant‑based proteins will become mainstream. As GLP‑1 therapies expand and users confront accelerated muscle loss, demand for high‑bioavailability protein is set to rise. Immunosciences’ focus on the 73 % of the population that is protein‑deficient could translate into rapid market penetration, prompting competitors to prioritize digestibility and clean‑label credentials in future product pipelines.